Story Stocks^®

Xenon Pharmaceuticals (XENE) is under heavy pressure today after voluntarily pausing new patient enrollment in its ongoing clinical studies in major depressive disorder (MDD) and bipolar depression (BPD). XENE also submitted a New Drug Application (NDA) for azetukalner in focal seizures, although the positive regulatory milestone is being overshadowed by the psychiatry pause.

• Azetukalner: The drug is being developed for the treatment of epilepsy, major depressive disorder, and bipolar depression. Azetukalner is a selective Kv7 potassium channel opener designed to increase potassium flow and reduce excessive neuronal excitability in the central nervous system.
• Pause: The pause comes after XENE observed neuropsychiatric adverse events in its Phase 3 MDD and BPD studies. XENE said the number and severity of events are consistent with azetukalner's known safety and tolerability profile, although these events had not been observed in the Phase 2 X-NOVA study in MDD. The precautionary pause is expected to be temporary, while currently enrolled patients will remain in the studies.
• NDA: The submission is based on positive clinical data from the Phase 2b X-TOLE and Phase 3 X-TOLE2 studies, with azetukalner demonstrating statistically significant reductions in monthly focal-seizure frequency compared with placebo.
• What's next: XENE is evaluating whether modifying the dosing regimen may improve azetukalner's tolerability profile in psychiatric indications. Completing X-NOVA2 is the next major test, helping determine efficacy and tolerability in MDD. Enrollment has been completed at approximately 360 patients, with topline data expected in Q1 2027.

Briefing.com Analyst Insight

While the NDA submission for azetukalner in focal seizures marks a major milestone for XENE, bringing it closer to a potential first approval and launch and its goal of becoming a fully integrated neuroscience company, that development is taking a back seat to the psychiatry pause today. XENE does not have any commercial products, so setbacks or potential signals that could delay development timelines can drive outsized moves in the stock. Importantly, XENE says the pause does not change its view of the epilepsy program and continues to characterize the psychiatry pause as precautionary and temporary. The X-NOVA2 readout in Q1 2027 will be important in determining azetukalner's efficacy and tolerability in MDD and helping guide how XENE proceeds with the broader psychiatry program.